LRT Capital Management LLC Sells 9,910 Shares of Repligen Corporation $RGEN

LRT Capital Management LLC lessened its position in shares of Repligen Corporation (NASDAQ:RGEN) by 50.5% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 9,709 shares of the biotechnology company’s stock after selling 9,910 shares during the period. Repligen comprises 1.4% of LRT Capital Management LLC’s holdings, making the stock its 27th largest position. LRT Capital Management LLC’s holdings in Repligen were worth $1,591,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently added to or reduced their stakes in the company. Measured Wealth Private Client Group LLC bought a new position in Repligen during the 3rd quarter worth about $29,000. Bayforest Capital Ltd bought a new position in Repligen during the 4th quarter worth about $32,000. Rachor Investment Advisory Services LLC bought a new position in Repligen during the 4th quarter worth about $33,000. Los Angeles Capital Management LLC bought a new position in Repligen during the 4th quarter worth about $36,000. Finally, Farther Finance Advisors LLC increased its holdings in Repligen by 61.8% during the 4th quarter. Farther Finance Advisors LLC now owns 335 shares of the biotechnology company’s stock worth $55,000 after purchasing an additional 128 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on RGEN. Weiss Ratings upgraded Repligen from a “sell (d)” rating to a “sell (d+)” rating in a report on Thursday, May 7th. Roth Mkm began coverage on Repligen in a report on Friday, April 17th. They issued a “buy” rating and a $160.00 price objective for the company. HSBC decreased their price objective on Repligen from $170.00 to $150.00 and set a “buy” rating for the company in a report on Wednesday, June 3rd. Canaccord Genuity Group decreased their price objective on Repligen from $165.00 to $145.00 and set a “hold” rating for the company in a report on Monday, April 20th. Finally, Royal Bank Of Canada began coverage on Repligen in a report on Thursday, May 14th. They issued an “outperform” rating and a $160.00 price objective for the company. Two equities research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and an average target price of $164.64.

Repligen Trading Down 2.1%

Shares of NASDAQ:RGEN opened at $130.59 on Friday. Repligen Corporation has a 52-week low of $100.99 and a 52-week high of $175.77. The company has a market capitalization of $7.37 billion, a P/E ratio of 145.10, a price-to-earnings-growth ratio of 2.51 and a beta of 1.09. The company has a 50-day simple moving average of $120.23 and a 200 day simple moving average of $137.90. The company has a debt-to-equity ratio of 0.26, a quick ratio of 7.78 and a current ratio of 9.20.

Repligen (NASDAQ:RGEN) last issued its earnings results on Tuesday, May 5th. The biotechnology company reported $0.48 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.38 by $0.10. Repligen had a net margin of 6.73% and a return on equity of 4.88%. The business had revenue of $194.26 million during the quarter, compared to the consensus estimate of $192.05 million. During the same period last year, the business posted $0.39 EPS. Repligen’s revenue was up 14.8% on a year-over-year basis. Repligen has set its FY 2026 guidance at 1.970-2.050 EPS. Sell-side analysts forecast that Repligen Corporation will post 1.99 earnings per share for the current year.

Repligen Profile

Repligen Corporation (NASDAQ:RGEN) is a life sciences company that develops and manufactures high-value consumable products for bioprocessing applications. Founded in 1981 and headquartered in Waltham, Massachusetts, the company specializes in technologies that support the development and production of biopharmaceuticals. Repligen’s offerings include chromatography resins, filtration membranes, single-use technologies and systems for downstream purification and upstream processing.

The company’s core product lines encompass Protein A affinity resins, designed for monoclonal antibody purification, and a portfolio of ion exchange, multimodal and hydrophobic interaction resins.